<DOC>
	<DOCNO>NCT00097331</DOCNO>
	<brief_summary>The study evaluate effectiveness safety investigational drug SB683699 treating patient relapse multiple sclerosis ( MS ) , use data magnetic resonance imaging ( MRI ) scan main measure .</brief_summary>
	<brief_title>Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion criterion : Diagnosis multiple sclerosis ( MS ) . Expanded Disability Status Score 0 6.5 . One relapse MS previous 12 month . Currently take medication MS ( apart use treat symptom ) . Exclusion criterion : Patients significantly abnormal laboratory test electrocardiogram ( ECG ) result . Subjects MRI scan . Women pregnant , breast feeding planning become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapse</keyword>
	<keyword>remit</keyword>
	<keyword>Relapsing-Remitting MS ( RRMS )</keyword>
</DOC>